CTRI/2022/03/041524Completed未知
A Multicenter, Randomized, Double-Blind, Three- Arm, Placebo-Controlled, Parallel Design, Study to Evaluate the Efficacy and Safety of Ketoconazole 2% Shampoo of Cadila Healthcare Limited with Ketoconazole Shampoo, 2% of Perrigo New York Inc. in Subjects with Tinea Versicolor
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Cadila Healthcare Limited
- Enrollment
- 425
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Ba/be
Eligibility Criteria
Inclusion Criteria
- •Subject will be eligible for inclusion in this study only if all of the following criteria apply:
- •1 Male or non-pregnant or non-lactating female subjects between 18 years of age or above.
- •2 Subjects with a clinical diagnosis of tinea versicolor and both of the following
- •A combined severity score of at least 4, with at least one of the following signs and symptoms rated at least 2, using the following scale:
- •Signs/symptoms Scale
- •Presence of infection with Malassezia furfur (Pityrosporum orbiculare or P. ovale) confirmed by a positive KOH cellophane tape test showing the characteristic spaghetti and meatballs ? appearance of the round budding yeast cells and short hyphae.
- •3. Subject able to understand the investigational nature of this study and give written informed consent prior to study entry.
- •4. Female of childbearing potential, have a negative urine pregnancy test at the baseline visit and willing to use an acceptable form of birth control including abstinence during the study.
- •5. Able to comply with study requirements in the opinion of Investigator.
Exclusion Criteria
- •Subject will not be eligible for inclusion in this study if any of the
- •following criteria apply
- •1. Has recent history or evidence of other fungal infections, including oral, vaginal or chronic mucocutaneous candidiasis, systemic fungal infections or dermatophyte infections that may interfere with of tinea versicolor.
- •2. Use of any systemic or topical antifungals, corticosteroids or immunosuppressive drugs within 30 days prior to baseline visit.
- •3. Use of any prescription or over the counter OTC, topical antifungal, anti-pruritus, corticosteroid, selenium sulfide or zinc pyrithione preparations within 14 days prior to baseline visit or used antihistamines that may interfere with the subjects ability to experience cutaneous sensations within 24 hours prior to baseline visit unless on a stable dose of antihistamine for at least 30 days.
- •4. Any known hypersensitivity or allergy to ketoconazole or other imidazole antifungals or other shampoos, soaps or cosmetics.
- •5. Treatment for tinea versicolor within the past six months that has been unresponsive to prescription topical or oral antifungals.
- •6. History of alcohol or other substance abuse within the last one year.
- •7. Any other clinical investigation using experimental drug within past 30 days of prior to baseline visit.
- •8. Institutionalized subject.
- •9. Live in the same household as currently enrolled subject.
- •10. Other severe acute or chronic medical or psychiatric conditions or laboratory abnormalities that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the subject inappropriate for entry into the trial.
Investigators
Similar Trials
Withdrawn
Phase 2
A Multi-Center, Randomized, Double-Blind, Three-Arm, Parallel-Group Trial to Assess the Efficacy and Safety of NTRA-9620 in Infants with Short Bowel Syndrome (SBS) Following Surgical ResectioSBSNL-OMON45489utrinia Ltd15
Active, not recruiting
Phase 1
Safety and Efficacy Study in Infants With SBSMedDRA version: 19.1Level: LLTClassification code 10025479Term: Malabsorption syndromeSystem Organ Class: 10017947 - Gastrointestinal disordersMedDRA version: 19.1Level: PTClassification code 10025476Term: MalabsorptionSystem Organ Class: 10017947 - Gastrointestinal disordersMedDRA version: 19.1Level: SOCClassification code 10017947Term: Gastrointestinal disordersSystem Organ Class: 10017947 - Gastrointestinal disordersShort Bowel syndromeEUCTR2015-000181-60-NLutrinia Ltd.150
Completed
Not Applicable
A study to evaluate the comparison of Tretinon cream to Retin A in the acne vulgarisCTRI/2021/11/038190Aleor Dermaceuticals Limited India500
Recruiting
Not Applicable
A study to evaluate the comparison of Tretinoin cream to Retin A and placebo in the acne vulgarisCTRI/2022/11/047525Aleor Dermaceuticals Limited India (Alembic Pharmaceuticals Limited)
Active, not recruiting
Phase 1
A Multi-center, Double-blind, Randomized, Three-Arm, Parallel-Group, Placebo Controlled Study to Assess the Efficacy and Safety of NTRA-2112 on Intestinal Malabsorption in Preterm InfantsIntestinal malabsorption in pre-term infantsEUCTR2014-002624-28-GButrinia Ltd.530